Nektar Therapeutics (BMV:NKTR)

Market Cap	22.92B
Revenue (ttm)	1.41B
Net Income (ttm)	-2.31B
Shares Out	n/a
EPS (ttm)	-164.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6
Average Volume	103
Open	1,135.00
Previous Close	n/a
Day's Range	1,135.00 - 1,135.00
52-Week Range	165.00 - 1,135.00
Beta	n/a
RSI	65.87
Earnings Date	Nov 6, 2025

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 61
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NKTR

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Financial numbers in USD